Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.

J Immunother Cancer · 2019 · PMC6383238 · PMID 30786924

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, antibodies against NY-ESO-1, TRP1/TYPR1 and TRP2/TYRP2 showed a trend towards higher levels in responders (Fig. 2 a, e, g).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.